Atrix/MediGene sign Leuprogel deal
An exclusive European marketing agreement has been announced betweenAtrix Laboratories and MediGene AG for Leuprogel (leuprolide acetate) to treat advanced prostate cancer. Leuprogel utilizes the Atrigel drug delivery system, which is injected into the body as a liquid, solidifies and releases predetermined doses of drug continuously for one, three or four months.
This agreement, valued at approximately $20 million, means Atrix now has access to 75% of the global market for hormone treatments for prostate cancer. Atrix submitted a New Drug Application to the US Food and Drug Administration in March for a one-month Leuprogel product, and expects to file an NDA for a three-month product later this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze